Alternatives to conventional or myeloablative chemotherapy in myelodysplastic syndrome

Research output: Contribution to journalArticlepeer-review


At present, the only 2 treatments that can prolong survival in patients with myelodysplastic syndrome (MDS) are allogeneic stem cell transplantation and intensive chemotherapy. Alternatives to myeloablative or conventional chemotherapy include: (1) supportive therapy, (2) stimulation of normal residual hematopoietic progenitors, and (3) manipulation of myelodysplastic hematopoiesis. These alternative therapeutic strategies can be accomplished using various therapeutic tools. Supportive therapy remains the mainstay in the management of MDS patients and desferrioxamine should be administered to individuals who have a regular need for blood transfusion. The only hematopoietic growth factors that can be useful in the treatment of selected MDS patients are recombinant human erythropoietin (rhEpo) and granulocyte colony-stimulating factor (G-CSF). Overall, 15% to 20% of patients with MDS respond to rhEpo treatment. Factors predicting response include serum erythropoietin levels

Original languageEnglish
Pages (from-to)134-138
Number of pages5
JournalInternational Journal of Hematology
Issue number2
Publication statusPublished - 2000


  • Cyclosporin a
  • Desferrioxamine
  • Erythropoietin
  • G-CSF
  • Immunosuppressive therapy
  • Myelodysplastic syndrome
  • Supportive therapy

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Alternatives to conventional or myeloablative chemotherapy in myelodysplastic syndrome'. Together they form a unique fingerprint.

Cite this